Good MorningEquity markets tread water on Wednesday ahead of the PPI report on Friday. The report could reinvigorate fear of inflation and the FOMC and spark another decline in the stock market. The S&P 500 is sitting on key support in the form of the 30-day EMA, a move below that could bring on more selling and drive the index down to the October lows.
The PPI report is not expected to show a decline in inflation and that is bad news. At current levels, PPI is supporting consumer-level inflation and may force the FOMC to hike rates by another 75 basis points at the meeting next week. As it is, the CME FedWatch Tool is pricing in a 75% chance the next hike will only be 50 basis points which is bad enough for the economy by itself. Featured: Crypto Genius: Forget bitcoin – this will be so much bigger (Ad) 
|
Stocks | | |
At MarketBeat, we do our best to deliver information about the stocks and stories that are moving the market. But we also want to make sure we give you information about the stocks that you care about the most – because those are the ones that are most likely to be in your portfolio.
While ... Read the Full Story |
|
From Our Partners | | We’ve got seven great summertime plays for you. These stocks are in a prime position to reward your portfolio… especially if you take action before summer is in full swing!
They cover summer-centric industries such as solar, home improvement, entertainment, travel, and more.
To keep you motivated during these summer months, we’d like to give you a FREE report revealing these companies – 7 Best Stocks to Own in Summer 2025. | | Get Your Copy of "7 Best Stocks to Own in Summer 2025" Here. |
|
Stocks | | | Wall Street ended a wobbly day of trading with more losses Wednesday, as a slide in technology companies helped pull stocks lower and Treasury yields fell broadly.
The S&P 500 slipped 0.2%, its fifth straight loss. The Nasdaq composite, which is heavily weighted with tech stocks,... Read the Full Story |
|
Markets | | |
In 1857, John Henry Hopkins Jr. wrote “Three Kings of Orient,” the popular Christmas carol more commonly known today as “We Three Kings.” Based on the Biblical Magi who bore gold, frankincense, and myrrh, the song is about the importance of sacrifice — and belie... Read the Full Story |
|
From Our Partners | | Cold War Discovery Could Unlock $100 Trillion in Wealth
Jeff recently traveled to an American ghost town to investigate this crazy Cold War story…
Because it could hold the key to the entire $100 trillion AI boom.
It involves an American ghost town with just 30 people…
And a new twist to the AI boom that could make a lot of people rich. | | Click here to see the details on what could be the biggest tech story of this decade. |
|
Stocks | | | Stocks edged lower on Wall Street in afternoon trading Wednesday, keeping major indexes on track to extend their recent losing streak into a fifth day.
The S&P 500 fell 0.2% as of 2:29 p.m. Eastern. The Dow Jones Industrial Average fell 10 points, or less than 0.1%, to 33,585 and ... Read the Full Story |
|
Markets | | |
Carvana Co. (NASDAQ: CVNA) shares are down nearly 66% since the beginning of the week on concerns that the company may be headed for bankruptcy. In fact, CVNA stock took a luld (limit up limit down) pause on the morning of December 7.
This came after Bloomberg reported that several of Carv... Read the Full Story |
|
From Our Partners | | I made a mistake.
A mistake I feel very foolish about.
After speaking with Donald Trump and some of his advisors, I believed him.
I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years.
But I was wrong. | | Let me show you exactly what we’re doing to prepare. |
|
Markets | | |
Shares of Spotify Technology SA (NYSE: SPOT) were rebounding Wednesday after declining 4.02% Tuesday.
The stock’s price has held above its November 4 low of $69.29. Does that mean we’ve heard the last of its downtrend?
Spotify attempted a rally in the summer, roughly in tandem ... Read the Full Story |
|
Markets | | | Japan’s economy contracted less than previously thought in the last quarter, weathering the country's latest big COVID wave with less damage than had been thought.
The Cabinet Office reported Thursday that the economy shrank at a 0.8% annual rate in July-September. That was better th... Read the Full Story |
|
Markets | | | Southwest Airlines said Wednesday that it is bringing back dividends for shareholders, which it suspended when the pandemic devastated the airline business in early 2020.
Dallas-based Southwest said in a regulatory filing that it will pay a quarterly dividend of 18 cents per share on ... Read the Full Story |
|
Markets | | | Italian confectioner Ferrero said Wednesday it is acquiring Wells Enterprises, one of the largest U.S. ice cream makers, in a deal that will broaden both companies’ offerings.
Wells, a 100-year-old family-owned company based in Le Mars, Iowa, makes Blue Bunny, Halo Top and other brand... Read the Full Story |
|
Markets | | |
The question of a Fed pivot isn’t if, it’s when because the FOMC can’t continue to hike rates indefinitely. In that scenario, economic activity would grind to a halt and recede, GDP would shrink and the global world order would collapse. No, the FOMC’s mission is to maintai... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
